<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484809</url>
  </required_header>
  <id_info>
    <org_study_id>0881A-101511</org_study_id>
    <nct_id>NCT00484809</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children</brief_title>
  <official_title>A Post-Marketing Surveillance Looking at Safety of Enbrel (Etanercept) in Adults With Active Rheumatoid Arthritis (RA) and Children With Juvenile Rheumatoid Arthritis (JRA).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      This postmarketing surveillance study will evaluate the safety profile of Enbrel (etanercept)
      in an Indian population. It will provide surveillance on a currently approved indication for
      Enbrel of reducing symptoms and inhibiting the progression of structural damage in patients
      with moderately to severely active rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel (Etanercept)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion in this study will be as per the approved indications in the package insert.

          -  Patients with moderately to severely active RA.

          -  Children with JRA who have had an inadequate response to one or more DMARDs.

        Exclusion Criteria:

          -  Known hypersensitivity to etanercept or any of its components.

          -  Known significant concurrent medical disease, including:

               -  Congestive heart failure, uncontrolled angina pectoris, recent history of
                  myocardial infarction

               -  Cancer or history of cancer

               -  Active infection

               -  Sepsis or risk of sepsis

               -  Active tuberculosis or a past history of tuberculosis

               -  Pancytopenia

          -  Females who are pregnant, breast feeding or at risk of pregnancy and not using a
             medically acceptable form of contraception.

          -  Patients who are planning to undergo elective surgery during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2007</study_first_submitted>
  <study_first_submitted_qc>June 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2007</study_first_posted>
  <last_update_submitted>December 11, 2007</last_update_submitted>
  <last_update_submitted_qc>December 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2007</last_update_posted>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>juvenile rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

